Dr. Stephen Scionti launches his U.S.-based prostate HIFU program in Sarasota, Florida by performing two HIFU procedures on the same day.

CHARLOTTE, N.C., DECEMBER 08, 2015 -- SonaCare Medical, LLC reports that two Sonablate® HIFU procedures were performed on Friday, December 4th, by Dr. Stephen Scionti in Sarasota, Florida. Dr. Scionti is collaborating with Vituro Health to bring their HIFU treatment program to the Sarasota Interventional Radiology Center.  This facility becomes the third location, among six systems installed to date, to perform a Sonablate® HIFU prostate tissue ablation procedure in the United States since the device received regulatory authorization in October. Dr. Scionti and team have another procedure scheduled for today, and plan to have ten performed before December 25th.

UCLH recognized for their advancements in prostate cancer diagnosis and treatment methods.

CHARLOTTE, N.C., DECEMBER 01, 2015 -- SonaCare Medical congratulates the University College London Hospitals NHS Foundation Trust on receiving the 2015 HSJ Acute Sector Innovation Award on November 18th. This prestigious award recognizes annually organizations that cultivate truly innovative methods of improving the patient care experience, and propose exciting enhancements to the medical landscape.

Michael J. Lazar, MD is the first physician to offer the recently FDA-cleared Sonablate® prostate tissue ablation procedure for men in San Francisco, CA.

CHARLOTTE, N.C., NOVEMBER 24, 2015 -- SonaCare Medical, LLC announces that a second location in the United States has performed a prostate tissue ablation procedure using the company's Sonablate® High Intensity Focused Ultrasound (HIFU) technology which FDA granted regulatory authorization for on October 9, 2015.

CHARLOTTE, N.C., OCTOBER  13, 2015 -- SonaCare Medical, LLC, a pioneer in minimally invasive high intensity focused ultrasound (HIFU) technologies, announced today that it received de novo clearance from the U.S. Food and Drug Administration (FDA) to market the Sonablate® 450  in the U.S. for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. SonaCare Medical expects to begin U.S. distribution this October.

Klinik für Prostata established as German demonstration center

JULY 9th 2015. CHARLOTTE, NC -- SonaCare Medical, global leader in high-intensity focused ultrasound (HIFU) ablation devices, announced today the purchase of a newest generation Sonasource with Sonablate® prostate ablation probes by Klinik für Prostata Therapie (Clinic for Prostate Therapy) in Heidelberg, Germany. SonaCare's Germany-based distribution partner Dr. Sennewald Medizintechnik GmbH facilitated the purchase and will collaborate with the clinic and SonaCare to form a German HIFU and Focal Therapy demonstration center in Heidelberg.

HIFU company

Contact

10130 Perimeter Pkwy, Suite 250
      Charlotte, NC 28216

(888) 874-4384

info@SonaCareMedical.com

Mon - Fri: 9:00 - 5:00

Latest News

10 April 2018

Over 120 urologists gather at Imperial College London to learn new diagnostic techniques and minimally invasive focal approaches for treating prostate cancer.

05 April 2018

CHARLOTTE, NC (PR NEWSWIRE) APRIL 05, 2018 – SonaCare Medical, the leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, announces the enrollment of over 100 patients from...